48Hour Discovery https://validator.w3.org/feed/docs/rss2.html Contact Us 48Hour Discovery Pioneers Late-Stage Peptide Reshaping to Advance Drug Discovery  Pre-screened Targets Our Pipeline Contact 48Hour Discovery AdvanCell and 48Hour Discovery Announce Collaboration and Exclusive Licensing Agreement to Develop a Lead-212 Alpha Radioligand Therapy Program Partnerships 48Hour Discovery files COVID related provisional patent. Press Releases Careers 48Hour Discovery Strengthens Leadership and Scientific Expertise with Three Key Appointments 48Hour Discovery Secures Funding from the City of Edmonton to Scale Innovation in Drug Discovery Alberta Cancer Foundation Awards 48Hour Discovery Breakthrough Fund Prize for Pioneering Cancer Research University of Alberta Empowers Breakthroughs: Assigns Comprehensive Patent Portfolio to 48Hour Discovery 48HD is profiled as a top glycomics company in a new Glyconet report. Speeding up drug discovery – Glyconet & 48Hour Discovery 48Hour Discovery Reveals New Insight into Cellular Regulation: Breakthrough Discovery for Controlling Cell Activity New Leadership for 48Hour Discovery: Rick Finnegan Named CEO 48Hour Discovery Accepted into Johnson & Johnson Innovation—JLABS Orano Med and 48Hour Discovery to Develop Innovative Peptide Receptor Radionuclide Therapy for Targeted Cancer Treatment Technology 48Hour Discovery and Fusion Pharmaceuticals to Develop Radiopharmaceuticals for the Treatment of Cancer Tumours Home Our Team Nova Cell Technology signs a joint research and technology transfer option contract with Canada’s 48Hour Discovery Inc. 48Hour Discovery and Quantum Intelligence Corp Join Forces to Form Quantum Intelligence Discovery (QID) – An AI-Powered Drug Discovery Venture 48Hour Discovery and Merck initiate drug discovery project Canadian company blazes a new trail to drug development 48Hour Discovery Secures Funding from Industry Commercialization Associate Program 48Hour Discovery’s Founder to speak at TIDES conference Patent Leveraging AI for Drug Discovery Information Technology Highlight of 48Hour Discovery in the Edmonton Journal Listen! To our recent interview with CBC Radio Active GlycoNet Agreement with 48Hour Discovery 48Hour Discovery Receives Funding from Industry r&D Associates Program 48Hour Discovery Enters into Agreement with TumorGenesis Join Us for an Inside Look of our Technology 48Hour Discovery and RayzeBio Announce Strategic Research Collaboration 48Hour Discovery CEO, Ratmir Derda, presents at Alberta Life Sciences Showcase 48Hour Discovery proud to sponsor the Canadian Glycomics Symposium 2018 48Hour Discovery announces the appointment of David Alton as Director of Business Development 48Hour Discovery names industry veteran John Dwyer as their new Vice President of Research 48Hour Discovery receives Government of Canada funding to develop technology that maximizes success of drug discovery 48Hour Discovery Announces COVID-19 research program Precision Therapeutics’ subsidiary TumorGenesis and its partner 48Hour Discovery Inc. receive Alberta Innovates Product Demonstration Program grant to support development of novel cancer treatments Edmonton company searches for antiviral compounds to treat COVID-19 GlycoNet-affiliated startup wins invitation to Government of South Korea’s K-Startup Grand Challenge 48Hour Discovery’s ‘molecule libraries’ help speed the search for new drugs